2011
DOI: 10.1039/c1cc10192g
|View full text |Cite
|
Sign up to set email alerts
|

Rational design of a Tn antigen mimic

Abstract: A novel Tn antigen mimic, in which the natural underlying amino acid has been replaced by the non-natural α-methylserine analogue, is reported. This derivative exhibits a similar affinity for a natural lectin as for the natural Tn and retains the bioactive conformation observed in the Tn-containing glycopeptides with anti-MUC1 antibodies.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

1
15
0

Year Published

2012
2012
2017
2017

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 24 publications
(16 citation statements)
references
References 44 publications
1
15
0
Order By: Relevance
“…[1] Considerable effort has thus been invested in delineating the impact of appended carbohydrates on the conformational preferences of proteins and peptides in solution and vice versa, [2] and also in understanding their interactions with their cognate receptors. [3] These endeavours are not straightforward, and success in rationalizing such processes has been possible only in a handful of well-studied cases. [4] Important insights into such questions have been gleaned from the study of glycoconjugate mimetics, whose interactions with cellular targets can impact a wide range of physiological phenomena, including fertilization, immune response, host–pathogen interactions, cell growth, and tumor metastasis.…”
mentioning
confidence: 99%
“…[1] Considerable effort has thus been invested in delineating the impact of appended carbohydrates on the conformational preferences of proteins and peptides in solution and vice versa, [2] and also in understanding their interactions with their cognate receptors. [3] These endeavours are not straightforward, and success in rationalizing such processes has been possible only in a handful of well-studied cases. [4] Important insights into such questions have been gleaned from the study of glycoconjugate mimetics, whose interactions with cellular targets can impact a wide range of physiological phenomena, including fertilization, immune response, host–pathogen interactions, cell growth, and tumor metastasis.…”
mentioning
confidence: 99%
“…Accordingly, new synthetic methods for obtaining Tn antigen as well as its counterpart analogues have been constantly investigated . To date, several Tn antigen analogues have been reported for use as vaccine constructs; examples include C‐glycosides, S‐glycosides, deoxyfluoro sugars, and Tn glycopeptide mimics containing unnatural amino acids . C‐glycosides and S‐glycosides are more stable toward enzymatic and chemical hydrolysis than natural Tn, because they have the interglycosidic oxygen atom replaced by a methylene group or by a sulfur atom, respectively .…”
Section: Introductionmentioning
confidence: 99%
“…Deoxyfluoro‐Tn analogues, possessing a fluorine atom instead of a sugar hydroxy group, are believed to enhance the immunogenicity of the antigen, as fluorine is absent in most organisms, as well as its bioavailability . The use of unnatural amino acids, such as α‐methylserine, or others containing long aliphatic side chains, has proven to be effective for obtaining unnatural Tn peptide‐linked vaccines with improved immunogenicity . The application of Cu I ‐assisted 1,3‐dipolar azide–alkyne cycloaddition (CuAAC) reactions between propargylated α‐GalNAc sugar and azido‐functionalized amino acids, or vice versa, represents another strategy for the synthesis of triazole‐derived Tn neoglycopeptide vaccines with advantageous physicochemical properties inherent to the triazole group …”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…This may be of special importance to peptide-based vaccines due to the short half-life of peptides. Peptides designed with NNAAs may adopt bioactive conformation with enhanced stability, and thus elicit immune response to wild-type tumor antigens (Vichier-Guerre et al, 2004;Corzana et al, 2011).…”
Section: Cancer Vaccinesmentioning
confidence: 99%